(Total Views: 83)
Posted On: 07/22/2025 3:06:53 PM
Post# of 29851
Opened a position in $NCNA
Open @ .05
Target .10
Stop Loss .04
Depending on the pressure we could be looking at .14 to .25
Company Overview
Sector: Biotechnology
Focus: Developing cancer treatments using proprietary ProTide technology
Lead Candidates:
NUC-7738: Targets melanoma, currently in Phase 2 trials
NUC-3373: Targets solid tumors and lung cancer, in Phase 1b/2 trials 2
Recent Catalysts
Warrant Cancellation: NCNA canceled all Series A warrants, reducing dilution risk1
ADS Ratio Change: Adjusting American Depository Share ratio to improve liquidity1
Clinical Expansion: New trials launched for NUC-7738 in PD-1 inhibitor-resistant melanoma2
Upcoming Data: Key clinical readouts expected in Q4 2025, which could be major catalysts 2
Its forming into a bull flag on the chart
Open @ .05
Target .10
Stop Loss .04
Depending on the pressure we could be looking at .14 to .25
Company Overview
Sector: Biotechnology
Focus: Developing cancer treatments using proprietary ProTide technology
Lead Candidates:
NUC-7738: Targets melanoma, currently in Phase 2 trials
NUC-3373: Targets solid tumors and lung cancer, in Phase 1b/2 trials 2
Recent Catalysts
Warrant Cancellation: NCNA canceled all Series A warrants, reducing dilution risk1
ADS Ratio Change: Adjusting American Depository Share ratio to improve liquidity1
Clinical Expansion: New trials launched for NUC-7738 in PD-1 inhibitor-resistant melanoma2
Upcoming Data: Key clinical readouts expected in Q4 2025, which could be major catalysts 2
Its forming into a bull flag on the chart
(0)
(0)
